Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

ent of elderly patients with high risk diffuse large B-cell lymphoma (DLBCL) relapse after treatment with R-CHOP. Treatment options for patients who are ineligible for autologous stem cell transplant are limited. In this analysis, of the 63 patients enrolled on the study, 39 patients had been treated with Zevalin. The median age is 75 years (range 62-86); Karnofsky performance status was <80 percent in 59 percent of patients with a median performance status of 70 percent; prognostic score was high-intermediate/high in 53 percent and 47 percent of patients, respectively. Moderate or high impact comorbidity is present in 86 percent. In the intent-to-treat population, progression-free (PFS) and overall survival (OS) were 59 percent and 65 percent, respectively, at 22 months. In the 39 patients who received Zevalin, PFS and OS were 78 percent and 82 percent, respectively, at 26 months. Responses improved in 11 patients who received Zevalin, with eight patients improving from an unconfirmed (CRu) to a confirmed complete response (CR) and three patients improving from a partial response (PR) to a CR/CRu. The side effects reported included blood count suppression: 26 percent and 36 percent grade 3/4 neutropenia, 15 percent grade 3 anemia, and 36 percent and 31 percent grade 3/4 thrombocytopenia. Six patients had delayed blood count recovery for more than 12 weeks. One patient developed myelodysplasia and two patients died after Zevalin was given, one from a suspected brain hemorrhage and one from congestive heart failure.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

R
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
(Date:9/30/2014)... Fat Burning Kitchen , the latest diet guide ... that is helping people learn the truth about so-called health ... in less than 24 hours has caught the attention of ... culture that is becoming so obsessed with diets and weight ... fact and fiction when it comes to health foods, eating ...
(Date:9/30/2014)... White Plains, NY (PRWEB) September 30, 2014 ... (HPCW) recently hosted its annual “In Celebration” gala, ... furthering the nonprofit’s mission of striving to provide ... individuals and families facing a serious or life-limiting ... Westchester Country Club in Rye, NY and recognized ...
(Date:9/30/2014)... 30, 2014 Two revolutionary procedures now being ... of gum disease a far less painful and far ... “If you’ve ever felt electric shock waves surge through your ... cold beverage, it’s possible you already know the impact of ... a general dentist in West Palm Beach, and a Fellow ...
(Date:9/30/2014)... An unprecedented, public-private partnership funded by the Department ... the development of better-run clinical trials and may ... brain injury, a condition affecting not only athletes ... public, ranging from youngsters to elders. , ... with a $17 million, five-year award from the ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 Healthpointe ... is now performing advanced foot and ankle reconstruction surgeries ... board-certified orthopedic surgeon, Dr. Cortés specializes in the diagnosis ... ankle injuries . She is also trained to perform ... their orthopedic needs. Dr. Cortés is also fluent in ...
Breaking Medicine News(10 mins):Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:US aims for traumatic brain injury clinical trial success 2Health News:US aims for traumatic brain injury clinical trial success 3Health News:US aims for traumatic brain injury clinical trial success 4Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 2Health News:Fellowship-Trained and Board-Certified Orthopedic Specialist Now Performing Advanced Foot & Ankle Reconstruction Surgeries 3
... Applications in Healthcare (C-PAHC) Now Accepting ... ... Records Institute introduces,today the Center for Cell Phone Applications in Healthcare ... phone applications in healthcare., (Logo: http://www.newscom.com/cgi-bin/prnh/20080825/NEM092LOGO ), ...
... best available option for people with hemochromatosis , , ... dismissed as a primitive form of medicine, in which ... humors by draining the life-sustaining fluid. , But there,s ... the preferred means of treatment. , Hemochromatosis is an ...
... invivodata to 2008 Pittsburgh 100, PITTSBURGH, Aug. ... patient reported outcomes (ePRO) solutions and,services for global ... has recognized the company in the "2008 Pittsburgh ... Western,Pennsylvania., "We see the Pittsburgh 100 as ...
... avoidance strategies , , MONDAY, Aug. 25 (HealthDay News) -- ... to ensure the safety of the more than 2.2 ... Academy of Allergy, Asthma & Immunology. , "Open and ... key ingredient to keeping food-allergic students out of harm. ...
... YORK, Aug. 25 HMS Holdings Corp. (Nasdaq:,HMSY) today ... Partners,2008 Healthcare Conference, which will be held September 3-5, ... Walter Hosp, SVP and Chief Financial Officer of HMS ... pm Eastern Time., A live broadcast of the ...
... 25 Dr. Anthony Ohotto, a physician,with Signature Hospice, ... "Limited life expectancy is no reason not to do ... the order as a health clearance, a,statement that the ... The Hospice team members at Signature Hospice had noted ...
Cached Medicine News:Health News:Medical Records Institute Unveils Platform for Studying Cell Phone Applications in Healthcare 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 3Health News:invivodata Recognized as One of Pittsburgh's Fastest Growing Private Companies 2Health News:Food Allergy Action Plan Can Keep Kids From Harm 2Health News:Signature Hospice Team Grants Patient's Unusual Wish 2
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Straight shafts with 15 mm long jaws. Serrated handle with polished finish. Smooth jaws....
Straight shafts with 6.5 mm tying platform. Crisscross serrated 1mm tips. Scalloped handle with dull finish....
Smooth tip forceps allow the surgeon to manipulate and smooth the corneal flap in Lasik procedures. Tip angled 10 mm from tip. Manufactured in titanium....
Medicine Products: